Imatinib Completed Phase 2 Trials for Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00500110Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
NCT00251225A Study of Imatinib and Docetaxel in Prostate Cancer
NCT00427999Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer